AMENDMENT NO. 3 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.Trial Agreement • August 15th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 3 to Clinical Trial Agreement (the “Amendment” or “Amendment 3”) is entered into as of April 20, 2016 (the “Effective Date”), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”).
AMENDMENT NO. 4 TO CLINICAL TRIAL AGREEMENT E2112 BETWEEN ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.Syndax Pharmaceuticals Inc • August 15th, 2016 • Pharmaceutical preparations
This Amendment No. 4 (the “Amendment” or “Amendment 4”) to Clinical Trial E2112 entered into on March 14, 2014 (the “Agreement”) is entered into as of April 20, 2016 (the “Effective Date”), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”).
AMENDMENT NO. 5 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.Trial Agreement • August 15th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 5 to Clinical Trial Agreement (the “Amendment” or “Amendment 5”) is entered into as of April 20, 2016 (the “Effective Date”), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”).
AMENDMENT NO. 6 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.Trial Agreement • August 15th, 2016 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 6 to Clinical Trial Agreement (the “Amendment” or “Amendment 6”) is entered into as of April 25, 2016 (the “Effective Date”), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”).
